Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.75 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.75 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.75 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28667548 | 0.96 | OPRM1 (0.80) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL2554375 | 0.93 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL30455750 | 0.86 | OPRM1 (1.00) | OPRM1OPRK1OPRL1 | |
| SCHEMBL8038486 | 0.86 | CHRNB4 (1.00) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL15794608 | 0.86 | OPRM1 (1.00) | OPRM1OPRK1OPRL1 | |
| SCHEMBL19410694 | 0.85 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL30364082 | 0.85 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL5427154 | 0.85 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL828730 | 0.85 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL19691160 | 0.85 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173699-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173699-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | ANDERSKEWITZ RALF | 2010-07-29 | — | — | US | disclosed |
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | ANDERSKEWITZ RALF | 2010-07-29 | — | — | US | disclosed |
| US-7723381-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723381-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-0208510-B1 | 1-SUBSTITUTED OXINDOLE-3-CARBOXAMINES AS ANTIINFLAMMATORY AND ANALGESIC AGENTS | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4791129-A | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4725616-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190767-A1 | Compounds for the treatment of inflammatory diseases | MALT1, IL1B, RORC | OPRM1 266/4885OPRK1 105/4885OPRL1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.